Mergers & Acquisitions ·
Nuvalent, Inc. entered into a merger agreement with GlaxoSmithKline LLC and its subsidiary, Harmony Row Acquisition…
NUVLNuvalent, Inc.
Nuvalent, Inc. entered into a merger agreement with GlaxoSmithKline LLC and its subsidiary, Harmony Row Acquisition Co., to be acquired in a cash transaction for $124.00 per share. The deal includes a tender offer for all outstanding Class A and Class B common stock, subject to a majority tender condition and antitrust clearance. Supporting stockholders, including Deerfield Management Company, L.P. and certain directors and officers, representing approximately 28% of Class A shares, have signed tender and support agreements. Nuvalent, Inc. is a biotechnology company focused on developing precision medicines for cancer.